Background: The rs368234815 polymorphism of interferon-λ4 (IFN-λ4) gene (IFNL4) is involved in HBV surface antigen (HBsAg) clearance in non-uremic subjects. The rs368234815 ΔG/ΔG genotype can express IFN-λ4 while the TT/TT genotype cannot. We investigated whether rs368234815 is associated with the development of HBsAg antibodies (anti-HBs) in response to vaccination or infection, and HBsAg loss after infection in uremic patients on extracorporeal dialysis.Research design and methods: Dialyzed patients (n = 467) were genotyped for rs368234815 by the polymerase chain reaction-restriction fragment length polymorphism method. Non-responders to HBV vaccination we compared with responders. HBsAg positive patients not able to develop anti-HBs we compared with individuals who eliminated HBsAg and generated anti-HBs. HBsAg positive patients we compared with subjects who eliminated HBsAg.Results: The ∆G allele was associated with the 1.6-fold higher risk not to develop anti-HBs titers ≥10 IU/L in response to HBV vaccination and infection (P = 0.016 adjusted for gender, age at dialysis onset, HCV RNA). The ∆G/∆G genotype indicated a higher probability of non-responsiveness to HBV vaccination than the TT/TT genotype (OR 2.64, 95%CI 1.01-6.87, adjusted P = 0.048).Conclusions: In extracorporeal dialysis patients, IFNL4 rs368234815 is associated with the capacity to produce protective anti-HBs titers in response to HBV vaccination.

中文翻译：

---

体外透析患者中​​干扰素-λ4基因的rs368234815多态性和针对乙型肝炎病毒表面抗原的抗体的产生。

背景：干扰素-λ4（IFN-λ4）基因（IFNL4）的rs368234815多态性与非尿毒症患者的HBV表面抗原（HBsAg）清除有关。rs368234815ΔG/ΔG基因型可以表达IFN-λ4，而TT / TT基因型则不能。我们研究了rs368234815是否与疫苗或感染引起的HBsAg抗体（抗HBs）的发展以及体外透析的尿毒症患者感染后HBsAg丢失有关。研究设计和方法：透析患者（n = 467）是基因分型的聚合酶链反应-限制性片段长度多态性法检测rs368234815。HBV疫苗接种无反应者与反应者进行了比较。我们将不能产生抗HBs的HBsAg阳性患者与消除HBsAg并产生抗HBs的个体进行比较。我们将HBsAg阳性患者与消除HBsAg的受试者进行了比较。结果：ΔG等位基因与因HBV疫苗接种和感染而未产生抗HBs滴度≥10IU / L的风险高1.6倍相关（P = 0.016调整后（性别，透析开始年龄，HCV RNA）。∆G / ∆G基因型表明对HBV疫苗无反应的可能性高于TT / TT基因型（OR 2.64，95％CI 1.01-6.87，调整后的P = 0.048）。结论：在体外透析患者中​​，IFNL4 rs368234815与对HBV疫苗反应产生保护性抗HBs滴度的能力有关。HCV RNA）。∆G / ∆G基因型表明对HBV疫苗无反应的可能性高于TT / TT基因型（OR 2.64，95％CI 1.01-6.87，调整后的P = 0.048）。结论：在体外透析患者中​​，IFNL4 rs368234815与对HBV疫苗反应产生保护性抗HBs滴度的能力有关。HCV RNA）。∆G / ∆G基因型表明对HBV疫苗无反应的可能性高于TT / TT基因型（OR 2.64，95％CI 1.01-6.87，调整后的P = 0.048）。结论：在体外透析患者中​​，IFNL4 rs368234815与抗HBV疫苗反应产生保护性抗HBs滴度的能力有关。